NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs NP 137 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- 20 Jan 2017 Status changed from active, no longer recruiting to recruiting.
- 10 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 08 Dec 2016 New trial record